Polymorphism of RAS in Patients with AT1-AA Mediated Steroid Refractory Acute Rejection by Geng Zhang & Jianlin Yuan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Polymorphism of RAS in  
Patients with AT1-AA Mediated  
Steroid Refractory Acute Rejection 
Geng Zhang and Jianlin Yuan 
Department of Urology, Xijing Hospital  
Fourth Military Medical University, Xi'an 
China 
1. Introduction 
Acute rejection is one major reason of the graft loss in renal transplantation. Most of the 
allograft rejections are due to the existence of the antibodies. The importance of the series 
tests of HLA and HLA antibodies associated with transplantation has been widely 
recognized. Although considerable rejection episodes can be explained by the appearance of 
the donor specific anti-HLA antibodies (DSA), it is reported that even in the case of ‘ideal’ 
HLA identical donor grafts transplanted into ‘ideal’ recipients, 23% are rejected within 10 
years [1]. So effect of HLA antibodies accounts for only some of the immunological failures 
of allograft and there must be large fraction of undetected antibodies against non-HLA 
mismatches. 
Despite various ways were used in the prevention of acute rejection, pulse steroid treatment 
remains the first-line therapy of all immumosuppresion projects and has a 60 to 70% success 
rate [2]. There are still recipients suffered from steroid refractory acute rejection (SRAR) and 
get worse. These rejections typically have an aggressive clinical course and are associated 
with graft loss [3]. Some of the patients would have to return to blood dialysis immediately 
and part of them die from complications. We detected antibodies in these patients and 
found that some of them do not have HLA antibodies and one of their marked 
characteristics is malignant hypertension. We presumed this is a special type of rejection. 
Thus, both immunologic and non-immunologic mechanisms for this specific type of rapid 
renal allograft dysfunction have to be considered. 
In case of the SRAR is appeared in a small part of the renal transplantation recipients, we 
presume that the genetic factors are involved it. It is reported that single nucleotide 
polymorphism (SNP) of some immune response related genes is involved in the 
development the acute rejection. The SNP of some genes can affect their functions by the 
changing either cytokine production or amino acid sequence. And the structure and 
function of some critical components would be altered concomitantly. The characteristic 
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Hypertension has been found to be an independent contributor in the progression of renal 
allograft failure in some studies [4, 5]. The presence of genetic abnormalities in blood 
pressure regulation could promote post-transplant hypertension and by that contribute to a 
more rapid loss of renal allograft function. The recipients’ blood pressure levels may depend 
on several factors, such as graft function, type, and dosage of immunosuppressive agents 
applied, previous rejection episodes, recurrence of the underlying nephropathy, and a 
previous history of hypertension [6]. The renin– angiotensin–aldosterone system (RAS) is a 
proteolytic cascade with an important role in blood pressure regulation and maintenance of 
fluid and electrolyte balance [7]. It was also reported that over activation of the RAS is 
linked to poor long-term renal transplant function and decreased graft survival times [8]. 
RAS polymorphisms associated with hypertension in certain groups have been identified 
[9]. We hypothesis that the occurrence of SRAR may be due to the over activating of RAS in 
a special group of recipients. And therefore, genes of the RAS deserve consideration. 
Among these the angiotensinogen (AGT), angiotensin-converting enzyme (ACE), 
angiotensin type 1 receptor (AT1R), and aldosterone synthase (CYP11B2) genes are of 
particular interest. Yet the prevalence and distribution, alone or combined, of the M235T-
AGT, I/D-ACE, A1166C-AT1R, or -344C/T-CYP11B2 polymorphisms and their relation 
with SRAR has not been well studied. 
In the studies of immunologic mechanism of acute vascular rejection, some data suggested 
that agonistic angiotensin type 1 (AT1) receptor autoantibodies (AT1-AA) may contribute to 
the pathogenesis of the rejection [10]. Some experiments implicated the role of renin-
angiotensin system in the regulation of specific immune responses and immune-mediated 
renal injuries [11]. And AT1 receptor blockade appeared to effectively attenuate the 
agonistic activity of the antibodies. 
So the SRAR may be a kind of specific rejection, whose origin, mechanism and results and 
treatment are all different from other types of rejections. Therefore, this study tried to 
determine whether or not gene polymorphisms of RAS are associated with steroid 
refractory acute rejection. Further more, by studying the gene-gene interaction, we searched 
the association of the occurrence of SRAR with the appearance of AT1-AA. 
2. Subjects and methods  
2.1 Study patients and biopsies 
A total 206 renal transplant recipients were included: 116 males and 90 females, mean age 
29.6±10.2 years range 22–55 years transplanted at Department of Urology of Xi Jing hospital, 
4th Military Medical University from January 1st, 2001, through December 31st, 2005. The 
transplants were first grafts in all cases. Serum samples obtained during rejection episodes 
were screened for donor specific anti-HLA antibodies and also agonistic antibodies 
targeting the AT1 receptor. This study was approved by the Ethics Committee of the 
Hospital, and all patients gave their oral informed consent while he or she was awaiting 
transplantation. 
Allograft-biopsy specimens were processed by standard techniques and graded according to 
the Banff97 criteria. C4d staining on paraffin-embedded sections was made according to a 
protocol described previously [12, 13]. 
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2.2 Immunosuppressive treatment 
Initial immunosuppressive therapy consisted of a calcineurin inhibitor, mycophenolate 
mofetil, methylprednisolone, and antibody against interleukin- 2 receptor for induction. All 
the recipients were treated with high dose pulse of methylprednisolone for 3 days with the 
dose of 0.5g, 0.5g, 0.25g in each day after the operation and a dose of 0.75g 
methylprednisolone was used on the operation day. Cyclosporine A or tacrolimus were 
introduced when serum creatinine levels were below 300μmol/L. Anti-proliferative agents, 
mycophenolate mofetil (1.5 g/day) or azathioprine (1–2 mg/kg/ day) were started on the 
day of transplantation. Prednisolone was reduced to 20mg daily after 7 days. Daily doses of 
CsA and tacrolimus were adjusted according to peak and trough blood levels respectively. 
High dose of methylprednisolone was utilized when the subject developed acute rejection 
after renal transplantation.  
Patients resistant to steroid were experienced further treatments. The further therapy 
includes protein A immunoadsorption (IA) and intravenous immune globulin. Patients who 
were positive for AT1-AA were added with angiotensin II Receptor Blockers (ARB). Patients 
initially treated with cyclosporine were switched to high dose tacrolimus when refractory 
rejection was detected. 
2.3 DNA extraction, PCR analysis and genotyping 
Genomic DNA prepared from blood cells using a standard column extraction technique. 
ACE I/D polymorphism in intron 16 of the ACE gene was determined as described 
previously [14]. In order to exclude mistyping of heterozygotes, all DD individuals were 
also examined using primers specific for the insertion variant. PCR products were resolved 
on a 2% agarose gel by ethidium bromide staining. 
AGT M 235 T was determined by PCR amplification according to a method described 
previously [15].The 165 bp PCR product was digested with TthIII at 37℃ for 3h and resolved 
on a 2.5% agarose gel by ethidium bromide staining. 
For the analysis of the AT1R (A1166C) polymorphism [16], a 410bp PCR product was 
digested with DdeI enzyme at 37℃for 3h and separated by electrophoresis in 2% agarose 
gel.  
CYP11B2 gene polymorphism was performed according to method described by Brand et al 
[17]. The PCR product was restricted with 5 U of the restriction endonuclease HaeIII over 2 
h at 37℃ and final product was electrophoresed in 2% agarose gel and visualized directly by 
ethidium bromide staining. The -344T allele lacks the HaeIII site that is present in the -344C 
allele and gives rise to a fragment of 273 bp rather than 202 bp.  
2.4 Antibody assays 
The detection of AT1-AA The peptides corresponding to the sequence of the second 
extracellular loop of the human AT1 receptor positions 165aa-191aa (I-H-R-N-V-F-F-I-E-N-
T-N-I-T-V-C-A-F-HY- E-S-Q-N-S-T-L) were synthesized by a peptide synthesis system [18]. 
The peptide was evaluated by HPLC analysis on a Vydac C-18 column, and 95% purity was 
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achieved. The ELISA assay of antibodies was performed according to the described 
previously [19].  
2.5 Statistics  
All statistical analyses were performed with the help of the SPSS 10.0 statistical software 
package. Categorical variables were assessed by the chi-square test. Survival curves for each 
group were calculated by the Kaplan-Meier method. Differences in genotype and allele 
distributions between groups were tested by the χ2 test. To compare the prevalence of SRAR 
among the genotypes of each polymorphism, genotypic odds ratios (OR) and 95% 
confidence intervals (CI) for SRAR were estimated using logistic regression analysis. Data 
are given as means with SD. In all statistical analysis the significance was considered 
significant when level (P) values were lower than 0.05. Test of Hardy–Weinberg equilibrium 
was performed in the subjects.  
3. Results  
All patients were classified into three groups according to the occurrence of SRAR. Two hundred 
and six renal transplant recipients were concerned by this study. Posttransplant 
hypertension was found in 102 cases (49.5%) of all patients. According to the presence of 
SRAR, patients were classified into two groups: group I (G I ), 19 patients (9.2%) underwent 
SRAR (10 men and 9 women), among them 14 had malignant hypertension. Group II (GII ) 
was the rest 187 patients who did not suffer from SRAR (104 men and 83 women), 16 of 
them had malignant hypertension, the difference between the two groups is significant. And 
150 normal people were set as control group (GIII). Baseline characteristics of the GI and GII 
were compared. No difference was observed in terms of age and sex in the donors. 
Moreover, no statistically significant differences were found between the GI and GII in 
terms of sex distribution, percentage of first kidney transplantation and cause of end-stage 
renal disease And there were no significant differences between the GI and GII for total 
number of HLA-mismatches, ischemia times (Table 1). 
The DD genotype of ACE and CC genotype of AT1R were risk factors for the development 
and progression of the SRAR. The genotype distributions of four key genes ACE I/D, AGT 
M235T, AT1R A1166C and CYP11B2 -344C/T of the RAS polymorphisms exhibited a 
nonsignificant difference with that predicted by the Hardy–Weinberg equilibrium in all 
cases. The significant differences of gene frequencies between all patients and control group 
were not observed. 
Differences between GI and GII and controls in genotype distributions were observed for 
both ACE gene polymorphisms with DD genotype and CC genotype of AT1R 
polymorphism being more prevalent in GI than in other two groups. Genotype distributions 
of other polymorphisms investigated in AGT and CYP11B2 genes did not differ between 
these three groups. The difference in allele distributions was only observed for AT1R 
A1166C with the C allele being more frequent in G I than G II and controls (42.1% v 29.9% 
and 30.1%) (Table 2). To test the association of ACE and AT1R gene polymorphisms with 
SRAR, genotypic ORs were calculated. Taking the II genotype of the ACE I/D 
polymorphism as a reference, the OR for SRAR associated with the ID genotype was 1.53  
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 Non-SRAR SRAR 
 (n=187) (n=19) 
Age (years) 36.5±11.6 37.7±12.5 
Male (%) 53 47 
IgG 9.3±2 10.4±2.8 
No. of HLA MM 3.6±1.2 3.2±1.8 
PRA positive (%) 7.6±1.2 7.5±1.5 
Duration of dialysis before NTx (mon) 20.3±16.2 23.6±18.6 
CIT(h) 10.6±7.1 11.6±7.3 
Cause of ESRD   
Chronic glomerulonephritis 56.9 50.6 
Hereditary 16.1 17.6 
High blood pressure 6.5 10.6 
IgA nephropathy 3.2 4.5 
Unknown 17.1 16.7 
CIT = Cold ischemia time; NTx=renal transplantation; HLA MM = HLA mismatch 
Table 1. Characteristics of patients involved in the study. 
   Genotypes  Alleles 
AGT M235T MM (%) MT(%) TT(%) M(%) 
GI  6 (31.6) 9 (47.3) 4(21.1) 21(55.3) 
GII  61 (32.6) 87(46.5) 39(20.9) 209(55.9) 
GIII 44 (29.3) 70 (46.7) 36(24) 158(52.7) 
ACE I/D + II (%) ID (%) DD (%) D (%) 
GI 3 (15.8) 9 (47.3) 7 (36.8) 19 (50) 
GII  55 (29.4) 108 (57.8) 24 (12.8) 156 (42.9) 
GIII  43 (28.7) 85 (56.7) 22 (14.6) 129 (43) 
AT1R A1166C* AA (%) AC (%) CC (%) C (%) 
GI 6 (31.6) 6 (31.6) 7 (36.8) 16 (42.1) 
G II  92 (49.2) 82 (43.9) 13 (8.0) 112 (29.9)  
G III  72 (48.0) 64 (42.7) 14 (9.3) 92 (30.1) 
CYP11B2 CC (%) TC (%) TT (%) C (%) 
GI 3 (15.8) 8 (42.1) 8 (42.1) 14 (36.8) 
GII  25 (13.3) 84 (44.9) 78 (41.8) 134 (35.8) 
GIII  19 (12.7) 67 (44.7) 64 (42.6) 105 (35.0)  
* : Significant difference in genotype and allele frequencies of GIversus both G II and G III (P＜0.01);  
+ : Significant difference in genotype frequencies of G I versus both G II and G III (P＜0.01). 
Table 2. Distributions of genotype and allele frequencies in each group. 
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(95% confidence interval [CI] 0.40-5.86) and the OR associated with the DD genotype was 
5.34 (95% CI 1.27-22.42), indicating a recessive effect of the D allele on risk (Table 3). A 
similar situation was observed for the A1166C polymorphism in the AT1R gene. Taking AA 
genotype as a reference, the OR for SRAR associated with the AC genotype was 1.15 (95% CI 
0.36-3.70) and that associated with the CC genotype was 8.34 (95% CI 2.43-28.69).  
The OR associated with the combination of DD and CC genotypes versus all other 
combinations was 5.92 (95% CI 2.85-12.37), that is, very similar to the one observed in the 
separate analyses of these two polymorphisms (Table 3).  
  OR 95% CI 
ACE I/D ID versus II 1.53 0.40-5.86 
 DD versus II 5.34 1.27-22.42* 
AT1R A1166C CC versus AA 8.34 2.43-28.69*  
 AC versus AA 1.15 0.36-3.70 
ACE I/D and DD+CC versus all other 5.92 2.85-12.37* 
AT1R A1166C genotypes on two loci   
CI = confidence interval; OR = odds ratio. * : P＜0.05. 
Table 3. Odds rations for the presence of SRAR by ACE I/D and AT1R A1166C. 
Malignant hypertension was companied with the AT1-AA mediated SRAR. We performed 
univariate analysis of the factors affecting SRAR to the overall group. The factors 
significantly associated with graft transplant failure were HLA mismatch >1 (P >0.05). 
Among the nineteen recipients suffered SRAR, fourteen patients occurred malignant 
hypertension. In the detection of AT1R antibodies and DSA, the former were invariably 
positive in the malignant hypertension recipients and the DSA negative in their peripheral 
blood. While the rest 4 cases of SRAR recipients have the peripheral DSA and 1 case with 
neither AT1-AA nor DSA. 
The demographic data from the 14 patients who were positive for AT1-receptor 
antibodies were compared with those for the 4 patients with donor-specific anti-HLA 
antibodies. As shown in Table 4, patients with anti-HLA antibodies were more likely to 
have staining for C4d in their renal biopsy specimens and had less rapid allograft loss. 
Otherwise, there were no significant differences in clinical or demographic characteristics 
between the two groups. 
The biopsy specimens from patients with malignant hypertension and refractory rejection 
who had no donor-specific anti-HLA antibodies (stained with hematoxylin and eosin) 
showed the evidence of tubulitis and intravascular inflammatory cells. Interlobular arteries 
were obstructed by swollen endothelial cells which underwent necrosis and vacuolation. 
The smooth muscle cells proliferated and the intima thickened greatly. Inflammatory cells 
can be seen inside the vascular and segmental veinlets. The atrophied glomcrulus were 
divided into subsections. Tubules were expanded with red cell cast inside it. The peritubular 
capillaries were aggregated with polymorph nuclear leukocytes. Interstitium was infiltrated 















Male sex (n) 8 2 
Cold-ischemia (h)   
Median 6.7 6.5 
Range 2.4-18.5 2.2-19.1 
No. of HLA mismatches   
Median 3 3 
Range 0-3 1-5 
PRA at transplantation (%)   
Median 5 6 
Range 0-7 0-9 
Age at transplantation (yr)   
Median 36.5 37.2 
Range 19-49 20-48 
Time from transplantation to rejections(days)   
Median 3 6 
Range 2-360 3-351 
C4d-positive (No.)* 3 4 
* : P<0.01. 
Table 4. Characteristics of patients with AT1-Receptor antibodies and patients with donor-
specific anti-HLA antibodies but without AT1R-Receptor antibodies. 
AT1-AA mediated SRAR was markedly associated with the prognosis of the renal transplant 
recipients. The occurrence of SRAR was analyzed for an association with the susceptibility to 
worsening renal graft function. A stable renal function was more often observed in 
recipients who did not suffered from SRAR than in GI. There was a striking effect of the 
SRAR and long-term stable graft function (Figure 2A), with more patients suffering from 
worsening renal function with the occurrence of SRAR (Kaplan-Meier, P<0.05). The analysis 
also discovered that the occurrence of SRAR is strongly associated with the appearance of 
the antibodies of AT1R. The χ2 analysis revealed that the positive of AT1-AA is strongly 
related to the appearance of SRAR. We also noticed that the frequency of the AT1R-C allele 
and ACE D-allele is comparable in SRAR group. Patients with anti-HLA antibodies had 
substantially better graft survival than did those who had malignant hypertension but did 
not have anti-HLA antibodies (Figure 2B). 
Treatment consisting of protein A immunoadsorption (IA), intravenous immune globulin, 
and 100 mg of losartan daily in nine patients with AT1R antibodies resulted in significantly 
improved allograft survival, as compared with that in patients receiving standard anti-
rejection treatment (Figure 2C). Serum from four patients with the longest rejection-free 
follow-up (who are still receiving losartan) became negative for AT1-receptor antibodies. 
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Fig. 1. Features of Refractory Rejection in Patients without Donor-Specific Anti-HLA 
Antibodies The biopsy specimens from representative patients showed the evidence of 
tubulitis and intravascular inflammatory cells. The atrophied glomcrulus were divided into 
subsections. Tubules were expanded with red cell cast inside it (Panel A). Inflammatory cells 
can be seen inside the vascular and segmental veinlets (Panel B). Interlobular arteries were 
obstructed by swollen endothelial cells which underwent necrosis and vacuolation. The 
smooth muscle cells proliferated and the intima thickened greatly. The peritubular 
capillaries were aggregated with polymorph nuclear leukocytes. Interstitium was infiltrated 
with inflammatory cells (Panel C and D).  
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Fig. 2. Graft survival in the Kaplan–Meier analysis was significantly decreased in the 
patients with SRAR compared with those who did not suffered from it (Panel A). The graph 
in Panel B demonstrates accelerated allograft loss in patients who had refractory vascular 
rejection with non-HLA antibodies, compared with patients who had vascular rejection and 
donor-specific anti-HLA antibodies. Graft survival in the Kaplan–Meier analysis was 
significantly increased in the patients with AT1-receptor antibodies who received losartan 
and IA, as compared with those who received nonspecific treatment (Panel C).  
4. Discussion 
The factors leading to SRAR are not fully understood, but they consist of humoral immune 
response and genetic factors [20]. We studied the SNP of RAS and AT1R antibodies and 
DSA in patients, and tested C4d on their biopsy specimens. The findings of this study 
suggest an association of RAS polymorphism and the occurrence of SRAR in renal 
transplantation recipients. The single nucleotide polymorphism of RAS may be one of the 
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non-immunologic mechanisms of the SRAR. Yet the appearance of autoantibody of AT1R 
may be one of the immunologic mechanisms of the occurrence of this type rejection. Our 
results support the hypothesis that there is an association between the occurrence of the 
SRAR and the appearance of the AT1-AA in recipients whose genotype of RAS performed 
certain polymorphism. The recipients with the DD genotype of ACE and CC genotype of 
AT1R may trend to suffer the AT1-AA mediated rejection. The process of the rejection may 
be improved by the application of ARB, coupled with protein A immunoadsorption and 
high dose intravenous immunoglobulin.  
The outcome of the renal transplantation was improved obviously with the use of CsA and 
FK506. Methylprednisolone was widely used in preventing and treatment of acute rejection 
and most recipients benefit from it. But there are still some patients who are refractory to the 
steroid treatment. Most of them have the similar characteristics including anuria after 
transplantation, malignant hypertension and graft function loss. It has been proved that 
many diseases have their own genotype polymorphism backgrounds. Genes that affect 
blood pressure regulation, mesangial or vascular proliferation or aspects of inflammatory 
response may play important roles in this complex syndrome. Genes determining the 
activity of a recipient’s renin–angiotensin system (RAS) may be alloantigen-independent 
factors that influence the kidney allograft function. 
Investigation of the genetics, physiology, and pharmacotherapeutics of RAS and its 
regulators has made it one of the most intensely studied molecular pathways of human 
diseases. The RAS is implicated in the development of a variety of human disorders, 
including cardiovascular diseases [21]. Inhibition of this system has had proven benefits in 
reducing the risk of cardiovascular endpoints [22], diabetes, and end stage renal disease 
(ESRD) [23]. Genetic variability in the RAS may modify renal responses to injury and 
disease progression. It seems some differential group of recipients is destined to lose their 
grafts faster. Our study was designed to elucidate the relationship between genetic RAS 
polymorphisms namely ACE I/ D, AGT M235T, AT1R A1166C and CYP11B2 and SRAR in 
Chinese renal transplant recipients. 
The angiotensin converting enzyme (ACE) gene displays an insertion/deletion 
polymorphism in intron 16, and homozygosity of the deletion allele is known to be 
associated with higher serum ACE levels [24]. The DD genotype of ACE gene is a risk factor 
for the progression of chronic renal failure in IgA nephropathy [25]. It has also been 
reported that patients with ACE (DD) and angiotensinogen AGT (TT) genotypes are linked 
to poorer long-term renal transplant function [26, 27]. Demonstrated survival benefits may 
be a result, in large measure, of the salutary effects of angiotensin converting enzyme (ACE) 
inhibition on the endothelium [28] and vascular smooth muscle cells [29]. A beneficial 
association of CAD progression in Caucasian pediatric renal transplant recipients with the II 
genotype and/or the presence of the I allele is also found [26, 30, 31]. Current evidence on 
the nature of the renal risk is associated with the D-allele, as also apparent from a large 
meta-analysis that addressed cardiovascular risk, indicates that the D-allele acts as a course-
modifying gene rather than as a disease-inducing gene [32].  
In the present study, the D allele of ACE is a risk factor for the development and progression 
of the SRAR while no significant relationship was found between ACE I/D polymorphism 
and CAD [33]. The result is in line with other studies that examined the effect of the ACE 
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I/D polymorphism on the progression of diabetic nephropathy [34], and the progression of 
chronic renal failure in immunoglobulin A nephropathy [35] and in adult polycystic kidney 
disease [36]. This effect of the D allele of ACE is also similar with the findings reported by 
Abdi et al [30] and Akc¸ay et al. [37] which found that ACE DD genotype was associated 
with poorer chronic transplant function and more rapid chronic progression. Some related 
results also have been reported by Barocci et al. [38] in pediatric transplant recipients and 
Gaciong et al. [39] in adult transplant recipients. Our data are consistent with these views. 
Thus, the presence of a D-allele does not appear to enhance renal risk in itself, but once a 
sequence of events leading to progressive renal function loss is initiated by whatever cause, 
its course is more rapid in presence of the D allele [40]. 
Angiotensin II has been proven to have growth factor-like and angiogenic activities [41] 
and these activities are mediated through the activation of the angiotensin type 1 receptor 
[42]. The AGT1R A1166C polymorphism was found to predict the systemic and renal 
response to angiotensin receptor antagonism and angiotensin II infusion in healthy 
subjects [43]. In the present study patients with the AGT1R C allele tended to have a 
worse preservation of graft function than patient homozygous for the A allele. Yet 
patients with the C allele exhibited a stronger response to losartan, showed a faster serum 
creatinine degression, and had a better response of the decent of the mean blood pressure 
compared with subjects homozygous for the AA allele, suggesting an increase in 
intrarenal angiotensin II activity with the AC/CC genotype. However, the treatment was 
neither randomly assigned nor blinded, and the numbers of patients are too small to 
permit us to draw firm conclusions. This would indicate that recipient AGT1R C allele 
may adversely affect renal outcome after kidney transplantation. Moreover, our data are 
in contrast with another report in which the C allele of AT1R dose not adversely affect 
renal response after transplantation [44]. However, we do not know the genotype of the 
donors because they were not genotyped. As the frequency of the A allele in the general 
population is high (71% in our patients), the probability of a recipient with the C allele 
receiving a kidney with the C allele is low. In the analysis of the results, the incidence of 
SRAR is very low (9.2%), the recipients with AT1-AA is even lower (6.8%). We suppose 
that the occurrence of SRAR may be based on the condition when the C recipient meets 
the C donor coincidently, and then the autoantibody of AT1-AA would be created in this 
group. Of course this is only an imagination need to be tested.  
There are many polymorphisms in the AGT gene located on chromosome 1q42–q43. In 
exon 2, a nonsynonymous substitution of T by C in codon 235 of the AGT gene, leads to a 
change from Methionine to Threonine. In Caucasians, African and Japanese populations, 
the T235 variant of this M235T polymorphism of this gene has been consistently 
associated with higher levels of angiotensinogen in plasma and an increased risk for 
hypertension [45, 46, 47]. 
The primary regulation of aldosterone synthesis is via the renin-angiotensin system, which 
is responsive to the state of the electrolyte balance and plasma volume. The -344T/C 
polymorphism in the CYP11B2 promoter region, the steroidogenic factor-1 binding site, was 
reported to be associated with blood pressure or aldosterone secretion. Some investigators 
found a positive association between the -344T polymorphism in the CYP11B2 gene and 
essential hypertension. Our study suggests that the CYP11B2 gene promoter region 
polymorphism and AGT M235T is not directly associated with SRAR. Therefore, this 
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polymorphism may not be a risk factor for the rejection or the malignant hypertension, at 
least not in the Chinese population. The lack of relationship between these two genotypes 
and early graft function in our study may indicate that other factors have major impacts in 
the setting of kidney transplantation. 
We also examine the relationship between the given RAS polymorphism and the emergency 
of peripheral AT1-AA of the recipients. Draun et al reported that AT1-receptor–mediated 
pathway may contribute to refractory vascular rejection [48]. Our results revealed that the 
recipients with D allele of the ACE and the C allele of the AT1R are inclined to have the 
AT1-AA. This phenomenon can partly explain the fact that only small percent of recipients 
have SRAR.  
Our report suggests that a SNP of the RAS component may contribute to the development 
of the steroid refractory acute rejection of kidney grafts. Individuals bearing D allele of ACE 
and C allele of AT1R may be sensitive to suffer steroid resistant acute rejection after renal 
transplantation. And the patients subjected to SRAR always produce AT1-AA. There is 
some statistical association between the appearance of AT1-AA and the D allele of ACE and 
C allele of AT1R. Patients with these types of antibodies have a less favorable prognosis, 
greater graft loss, and poorer long-term function as compared with patients with DSA alone. 
The treatment against such antibody mediated immune response is necessary and effective. 
We speculate the AT1-AA may have been produced when the subjects experienced 
preeclampsia or renal transplantation before or for other reasons. The importance of the 
detection of the genotype of ACE and AT1R and AT1-receptor antibodies in patients on a 
waiting list for a transplant might be comparable with the detection of PRA in identifying 
risk factors for refractory rejection. 
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